There is a particularly acute need to identify patients who benefit most from neoadjuvant immunotherapy, as predictive biomarkers in the metastatic setting such as PD-L1 have not translated to early-stage disease, and immunotherapy may be associated with irreversible, lifelong irAEs in patients with curable breast cancer. This evidence concerns the gene CD274 and breast carcinoma.